Literature DB >> 16521224

Removal selectivity of Prometheus: a new extracorporeal liver support device.

Kinan Rifai1, Thomas Ernst, Ulrich Kretschmer, Hermann Haller, Michael Peter Manns, Danilo Fliser.   

Abstract

AIM: To evaluate whether treatment with the Prometheus reg system significantly affects cytokines, coagulation factors and other plasma proteins.
METHODS: We studied nine patients with acute-on-chronic liver failure and accompanying renal failure. Prometheus reg therapy was performed on 2 consecutive days for up to 6 h in all patients. Several biochemical parameters and blood counts were assessed at regular time points during Prometheus reg treatment.
RESULTS: We observed a significant decrease of both protein-bound (e.g. bile acids) and water-soluble (e.g. ammonia) substances after Prometheus reg therapy. Even though leukocytes increased during treatment (P<0.01), we found no significant changes of C-reactive protein, interleukin-6, and tumor necrosis factor-alpha plasma levels (all P>0.5). Further, antithrombin 3, factor II and factor V plasma levels did not decrease during Prometheus reg therapy (all P>0.5), and the INR remained unchanged (P=0.4). Plasma levels of total protein, albumin, and fibrinogen were also not altered during Prometheus reg treatment (all P>0.5). Finally, platelet count did not change significantly during therapy (P=0.6).
CONCLUSION: Despite significant removal of protein-bound and water-soluble substances, Prometheus reg therapy did not affect the level of cytokines, coagulation factors or other plasma proteins. Thus, the filters and adsorbers used in the system are highly effective and specific for water-soluble substances and toxins bound to the albumin fraction.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16521224      PMCID: PMC4066161          DOI: 10.3748/wjg.v12.i6.940

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  8 in total

1.  Prognostic value of cytokines in SIRS general medical patients.

Authors:  M Rodríguez-Gaspar; F Santolaria; A Jarque-López; E González-Reimers; A Milena; M J de la Vega; E Rodríguez-Rodríguez; J L Gómez-Sirvent
Journal:  Cytokine       Date:  2001-08-21       Impact factor: 3.861

2.  Application of Molecular Adsorbents Recirculating System to remove NO and cytokines in severe liver failure patients with multiple organ dysfunction syndrome.

Authors:  Li-Min Guo; Jing-Yuan Liu; Dao-Zhen Xu; Bao-Shun Li; Hao Han; Ling-Hang Wang; Wei-Yan Zhang; Lian-He Lu; Xia Guo; Feng-Xia Sun; Hong-Yu Zhang; Xiao-Dong Liu; Jian-Ping Zhang; Yun Yao; Zhong-Ping He; Min-Min Wang
Journal:  Liver Int       Date:  2003       Impact factor: 5.828

Review 3.  Prospects for extracorporeal liver support.

Authors:  R Jalan; S Sen; R Williams
Journal:  Gut       Date:  2004-06       Impact factor: 23.059

Review 4.  Artificial liver support: potential to retard regeneration?

Authors:  Emma J Mullin; Matthew S Metcalfe; Guy J Maddern
Journal:  Arch Surg       Date:  2004-06

5.  Fractionated plasma separation and adsorption system: a novel system for blood purification to remove albumin bound substances.

Authors:  D Falkenhagen; W Strobl; G Vogt; A Schrefl; I Linsberger; F J Gerner; M Schoenhofen
Journal:  Artif Organs       Date:  1999-01       Impact factor: 3.094

6.  A new procedure for the removal of protein bound drugs and toxins.

Authors:  J Stange; S Mitzner; W Ramlow; T Gliesche; H Hickstein; R Schmidt
Journal:  ASAIO J       Date:  1993 Jul-Sep       Impact factor: 2.872

Review 7.  Liver regeneration.

Authors:  N Fausto
Journal:  J Hepatol       Date:  2000       Impact factor: 25.083

8.  The molecular adsorbents recycling system as a liver support system based on albumin dialysis: a summary of preclinical investigations, prospective, randomized, controlled clinical trial, and clinical experience from 19 centers.

Authors:  Jan Stange; Tarek I Hassanein; Ravindra Mehta; Steffen R Mitzner; Robert H Bartlett
Journal:  Artif Organs       Date:  2002-02       Impact factor: 3.094

  8 in total
  9 in total

1.  Artificial and bioartificial liver support.

Authors:  Gesine Pless
Journal:  Organogenesis       Date:  2007-01       Impact factor: 2.500

Review 2.  Liver support systems: will they ever reach prime time?

Authors:  Rafael Bañares; María-Vega Catalina; Javier Vaquero
Journal:  Curr Gastroenterol Rep       Date:  2013-03

Review 3.  Role of artificial liver support in hepatic encephalopathy.

Authors:  V Stadlbauer; G A K Wright; R Jalan
Journal:  Metab Brain Dis       Date:  2008-12-21       Impact factor: 3.584

4.  Thermodynamic considerations in solid adsorption of bound solutes for patient support in liver failure.

Authors:  John F Patzer
Journal:  Artif Organs       Date:  2008-07       Impact factor: 3.094

Review 5.  Innate immune dysfunction in acute and chronic liver disease.

Authors:  Bettina Leber; Ursula Mayrhauser; Michael Rybczynski; Vanessa Stadlbauer
Journal:  Wien Klin Wochenschr       Date:  2009       Impact factor: 1.704

6.  Effect of extracorporeal liver support by MARS and Prometheus on serum cytokines in acute-on-chronic liver failure.

Authors:  Vanessa Stadlbauer; Peter Krisper; Reingard Aigner; Bernd Haditsch; Aleksandra Jung; Carolin Lackner; Rudolf E Stauber
Journal:  Crit Care       Date:  2006       Impact factor: 9.097

7.  Extracorporeal liver assist device to exchange albumin and remove endotoxin in acute liver failure: Results of a pivotal pre-clinical study.

Authors:  Karla C L Lee; Luisa A Baker; Giacomo Stanzani; Hatim Alibhai; Yu Mei Chang; Carolina Jimenez Palacios; Pamela J Leckie; Paola Giordano; Simon L Priestnall; Daniel J Antoine; Rosalind E Jenkins; Christopher E Goldring; B Kevin Park; Fausto Andreola; Banwari Agarwal; Rajeshwar P Mookerjee; Nathan A Davies; Rajiv Jalan
Journal:  J Hepatol       Date:  2015-05-01       Impact factor: 25.083

Review 8.  Acute kidney injury in children with chronic liver disease.

Authors:  Akash Deep; Romit Saxena; Bipin Jose
Journal:  Pediatr Nephrol       Date:  2018-03-01       Impact factor: 3.714

Review 9.  Bench-to-bedside review: current evidence for extracorporeal albumin dialysis systems in liver failure.

Authors:  Constantine J Karvellas; Noel Gibney; Demetrios Kutsogiannis; Julia Wendon; Vincent G Bain
Journal:  Crit Care       Date:  2007       Impact factor: 9.097

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.